[go: up one dir, main page]

DK1604016T3 - In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler - Google Patents

In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler

Info

Publication number
DK1604016T3
DK1604016T3 DK04715780T DK04715780T DK1604016T3 DK 1604016 T3 DK1604016 T3 DK 1604016T3 DK 04715780 T DK04715780 T DK 04715780T DK 04715780 T DK04715780 T DK 04715780T DK 1604016 T3 DK1604016 T3 DK 1604016T3
Authority
DK
Denmark
Prior art keywords
cells
monocytes
dendritic
csf
dendritic cells
Prior art date
Application number
DK04715780T
Other languages
Danish (da)
English (en)
Inventor
Benjamin A Tjoa
Marnix L Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Application granted granted Critical
Publication of DK1604016T3 publication Critical patent/DK1604016T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK04715780T 2003-02-27 2004-02-27 In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler DK1604016T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45101503P 2003-02-27 2003-02-27
PCT/US2004/006119 WO2004076651A2 (fr) 2003-02-27 2004-02-27 Generation de cellules dendritiques a partir de cellules precurseurs dendritiques monocytiques, au moyen du facteur gm-csf, en l'absence de cytokines supplementaires

Publications (1)

Publication Number Publication Date
DK1604016T3 true DK1604016T3 (da) 2009-05-18

Family

ID=32927693

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04715780T DK1604016T3 (da) 2003-02-27 2004-02-27 In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler

Country Status (20)

Country Link
US (4) US8389278B2 (fr)
EP (1) EP1604016B1 (fr)
JP (1) JP4762887B2 (fr)
KR (2) KR101201875B1 (fr)
CN (1) CN1784488B (fr)
AT (1) ATE420946T1 (fr)
AU (2) AU2004214896A1 (fr)
BR (1) BRPI0407900A (fr)
CA (1) CA2517295C (fr)
CY (1) CY1109099T1 (fr)
DE (1) DE602004019057D1 (fr)
DK (1) DK1604016T3 (fr)
ES (1) ES2321939T3 (fr)
IL (1) IL170512A (fr)
MX (1) MXPA05009178A (fr)
NZ (1) NZ542071A (fr)
PL (1) PL209998B1 (fr)
RU (1) RU2364625C2 (fr)
TW (1) TW200506061A (fr)
WO (1) WO2004076651A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
WO2004053072A2 (fr) * 2002-12-06 2004-06-24 Northwest Biotherapeutics, Inc. Administration de cellules dendritiques partiellement matures in vitro pour le traitement de tumeurs
EP1670513B1 (fr) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Inhibiteurs de cox-2 et cellules dendritiques pour l' utilisation dans le traitement du cancer
WO2005043155A1 (fr) * 2003-10-21 2005-05-12 Cedars-Sinai Medical Center Systeme et methode pour le traitement du cancer, notamment des cancers du systeme nerveux central
US7790039B2 (en) 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
KR20150082688A (ko) * 2005-12-08 2015-07-15 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
EP1806395A1 (fr) * 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation de céllules dendritiques
CA2700573C (fr) * 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Vaccins comprenant des antigenes de cellules souches cancereuses et procedes
WO2008039974A2 (fr) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Vaccins contre le cancer et méthodes de vaccination
EP1920781B1 (fr) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprenant un microorganisme contenant core-1 et son utilisation pour le traitement des tumeurs
KR100896747B1 (ko) 2007-05-30 2009-05-11 동아대학교 산학협력단 후코이단 또는 그 유사체를 함유하는 수지상 세포의 성숙화유도용 조성물
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
ES2565779T3 (es) * 2008-09-02 2016-04-06 Cedars-Sinai Medical Center Epítopos CD133
JP2010063404A (ja) * 2008-09-10 2010-03-25 Olympus Corp 幹細胞の分離方法
FR2940451B1 (fr) * 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
WO2010129895A2 (fr) * 2009-05-07 2010-11-11 Immunocellular Therapeutics, Ltd. Epitopes des cd133
ES2711504T3 (es) * 2009-07-24 2019-05-06 Rhode Island Hospital Vacunas de células dendríticas para tumores que expresan asparaginil-beta-hidroxilasa
EP2498795B1 (fr) * 2009-10-12 2016-12-07 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Granulysine dans l'immunothérapie
CA2793458A1 (fr) * 2010-03-15 2011-09-22 The Trustees Of The University Of Pennsylvania Systeme et procede de preparation et de conservation de cellules dendritiques matures activees
RU2458985C1 (ru) * 2011-03-18 2012-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью
CN109536446B (zh) 2012-02-10 2022-08-02 医疗法人社团博心厚生会 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
DK3173420T3 (da) * 2014-07-23 2021-10-18 Nat Ct Nanoscience & Technology China Polypeptid og polypeptidkompleks til undertrykkelse af tumormetastase og behandling af leukæmi samt fremgangsmåde til fremstilling deraf og anvendelse deraf
CN104098652B (zh) * 2014-07-23 2016-11-09 国家纳米科学中心 一种抑制肿瘤转移的多肽和多肽复合物、其制备方法及其应用
CN114774356A (zh) 2015-06-30 2022-07-22 西北生物治疗药物公司 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞
WO2017048875A1 (fr) 2015-09-15 2017-03-23 Northwest Biotherapeutics, Inc Procédés relatifs à des compositions de cellules dendritiques activées et traitements immunothérapeutiques pour des sujets atteints de cancers avancés
CN105483084A (zh) * 2016-01-04 2016-04-13 英普乐孚生物技术(上海)有限公司 肿瘤抗原靶向性dc细胞的制备方法
CN112912389B (zh) 2018-06-19 2024-04-19 H·李·莫菲特癌症中心和研究所公司 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗
KR102159766B1 (ko) * 2018-11-12 2020-09-24 조선대학교산학협력단 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법
EP3945815A4 (fr) * 2019-04-03 2023-04-19 Akron Biotechnology, LLC Milieux de cryoconservation et de culture cellulaire
CN114096260A (zh) * 2019-07-12 2022-02-25 国立大学法人九州大学 心肌收缩改善治疗法和心肌细胞死亡抑制法的开发
CN114980928B (zh) * 2019-11-18 2025-03-07 儿童医学中心公司 过度活化的树突状细胞可实现持久的基于过继性细胞转移的抗肿瘤免疫
AU2022269982A1 (en) * 2021-05-07 2023-11-30 NANOFAENTECH CO., Ltd. Method for culturing dendritic cells
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法
US20230287346A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
US20230287448A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
CN118389430A (zh) * 2024-04-12 2024-07-26 广东壹加再生医学研究院有限公司 一种高抗肿瘤特异性dc-cik细胞的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3683956D1 (de) * 1985-06-11 1992-04-02 Us Commerce In einem serumfreien medium in suspension kultivierte humane monozyten.
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2003010292A2 (fr) * 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Procedes et appareil pour l'enrichissement et la culture de precurseurs cellulaires dendritiques monocytaires
EP2322603B1 (fr) * 2001-09-06 2019-10-16 NorthWest Biotherapeutics, Inc. Compositions et procédés d'activation de cellules dendritiques monocytaires et de lymphocytes T pour une réponse de type Th1
HUE031517T2 (en) 2002-06-19 2017-07-28 Northwest Biotherapeutics Inc Cross-flow filtration equipment and procedures for leukocyte enrichment
EP1597356A4 (fr) * 2003-02-10 2007-07-11 Northwest Biotherapeutics Inc Cellules presentant l'antigene cd14+ de culture

Also Published As

Publication number Publication date
CN1784488A (zh) 2006-06-07
US20130273654A1 (en) 2013-10-17
DE602004019057D1 (de) 2009-03-05
US20210102169A1 (en) 2021-04-08
CA2517295A1 (fr) 2004-09-10
US20040203143A1 (en) 2004-10-14
KR20050107471A (ko) 2005-11-11
CA2517295C (fr) 2016-01-12
US10731130B2 (en) 2020-08-04
KR101201875B1 (ko) 2012-11-15
WO2004076651A2 (fr) 2004-09-10
JP4762887B2 (ja) 2011-08-31
US9102917B2 (en) 2015-08-11
AU2004214896A1 (en) 2004-09-10
RU2364625C2 (ru) 2009-08-20
EP1604016A4 (fr) 2006-03-08
EP1604016A2 (fr) 2005-12-14
IL170512A (en) 2013-12-31
US11827903B2 (en) 2023-11-28
JP2006519021A (ja) 2006-08-24
AU2010201319A1 (en) 2010-04-29
KR20110106474A (ko) 2011-09-28
HK1086597A1 (en) 2006-09-22
PL378291A1 (pl) 2006-03-20
ATE420946T1 (de) 2009-01-15
MXPA05009178A (es) 2006-03-08
US20160024472A1 (en) 2016-01-28
AU2010201319B2 (en) 2012-09-06
BRPI0407900A (pt) 2006-03-21
US8389278B2 (en) 2013-03-05
WO2004076651A3 (fr) 2005-03-10
CY1109099T1 (el) 2014-07-02
PL209998B1 (pl) 2011-11-30
EP1604016B1 (fr) 2009-01-14
CN1784488B (zh) 2010-07-28
ES2321939T3 (es) 2009-06-15
NZ542071A (en) 2007-11-30
RU2005129561A (ru) 2006-03-10
TW200506061A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
DK1604016T3 (da) In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler
Đokić et al. Mesenchymal stem cells from periapical lesions modulate differentiation and functional properties of monocyte‐derived dendritic cells
SG152273A1 (en) Pdx1 expressing endoderm
Khosravi et al. Induction of CD4+ CD25+ FOXP3+ regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation
SG149061A1 (en) Definitive endoderm
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
EP2626415A3 (fr) Procédés d'expansion de populations de cellules myéloïdes et leurs utilisations
NZ598657A (en) Anti-il-6 antibodies, compositions, methods and uses
NZ600075A (en) Means and methods for influencing the stability of antibody producing cells
PH12020551151A1 (en) Method of producing natural killer cells and composition for treating cancer
WO2003083089A3 (fr) Cellules tolerogenes presentant des antigenes
CN116004533B (zh) iNKT细胞的激活扩增方法及其培养基组合
EP1572989B1 (fr) Lignee de cellules dendritiques gen2.2
WO2004072262A3 (fr) Cellules presentant l'antigene cd14+ de culture
AU2001259744A1 (en) Compositions and methods for producing antigen-presenting cells
EP2377922A3 (fr) Endoderme exprimant PDX1
O'Connell et al. Type‐1 polarized nature of mouse liver CD8α–and CD8α+ dendritic cells: tissue‐dependent differences offset CD8α‐related dendritic cell heterogeneity
EP2484759A3 (fr) Procédés de repliement des glycosyl-transférases des mammifères
WO2003100010A3 (fr) Croissance et maintenance de cellules progenitrices sans cytokine
MX2007005928A (es) Metodos para la produccion de celulas de mamiferos.
CA2442300A1 (fr) Cellule dendritique lymphoide cd8.alpha. + differenciee d'une cellule souche hematopoietique humaine et procede de differenciation
EP1927657A3 (fr) Compositions et procédés pour la production de cellules présentant un antigène
ATE263833T1 (de) Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen
Kronsteiner et al. Suppression of Differentiation and Maturation of Dendritic Cells: Stem Cells from Different Sources Vary in Their Effect